GLP1R and cardiovascular disorder: Given the prevalence and incidence of T2D and the disease-associated post-diagnosis complications such as cardiovascular disease (CVD), and the observation that GLP-1 activity is retained in T2D whereas gastric inhibitory polypeptide (GIP) activity is greatly reduced, research was conducted to develop a new therapeutic strategy for T2D treatment using GLP-1–based therapies8–10,14.